Clinical Trial: Comparison of Bupivacaine and Exparel for Carpal Tunnel Release

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional

Official Title: Does Long-Acting Liposomal Bupivacaine Provide Improved Pain Relief Over Bupivicaine Alone in Carpal Tunnel Release?

Brief Summary:

Carpal tunnel syndrome is one of the most common surgeries performed per year in the United States, accounting for over 600,000 surgeries. The procedure is commonly performed under light sedation and local anesthesia. Bupivicaine, a long acting local anesthetic, has been used to allow extended pain relief for 8-10 hours after carpal tunnel release. Exparel, a liposomal bupivicaine formulation, has been documented to provide pain relief for up to 72 hours post-operatively. By decreasing post-operative pain through the use of a long-acting local anesthetic, the use of narcotic pain medications may be decreased and patient satisfaction scores may increase.

The purpose of this study is to prospectively compare bupivicaine and liposomal bupivicaine with respect to post-operative pain control, narcotic usage, and patient satisfaction after carpal tunnel release.

Detailed Summary:
Sponsor: University of Pittsburgh

Current Primary Outcome: Pain [ Time Frame: Starting immediately after surgery and then every 8 hours for 10 days ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Pittsburgh

Dates:
Date Received: May 12, 2014
Date Started: May 2015
Date Completion:
Last Updated: January 4, 2016
Last Verified: January 2016